Adit Ginde
Concepts (627)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emergency Service, Hospital | 89 | 2025 | 2050 | 8.520 |
Why?
| | Outpatients | 17 | 2025 | 393 | 5.250 |
Why?
| | Sepsis | 21 | 2024 | 611 | 4.110 |
Why?
| | Critical Illness | 24 | 2025 | 807 | 4.090 |
Why?
| | Hospitalization | 55 | 2025 | 2195 | 3.870 |
Why?
| | Vitamin D | 22 | 2025 | 395 | 3.410 |
Why?
| | Vitamin D Deficiency | 14 | 2021 | 184 | 2.810 |
Why?
| | Intubation, Intratracheal | 19 | 2025 | 259 | 2.480 |
Why?
| | Adult | 165 | 2025 | 37616 | 2.400 |
Why?
| | Emergency Medical Services | 15 | 2025 | 548 | 2.320 |
Why?
| | Influenza, Human | 16 | 2025 | 624 | 2.300 |
Why?
| | Emergency Medicine | 13 | 2023 | 224 | 2.280 |
Why?
| | Humans | 295 | 2025 | 136783 | 2.270 |
Why?
| | Cholecalciferol | 7 | 2024 | 60 | 2.270 |
Why?
| | Wounds and Injuries | 10 | 2025 | 752 | 2.270 |
Why?
| | Aged | 119 | 2025 | 23729 | 2.250 |
Why?
| | Hyperoxia | 4 | 2023 | 90 | 2.220 |
Why?
| | Hospital Mortality | 21 | 2025 | 900 | 2.170 |
Why?
| | Physician Assistants | 7 | 2014 | 92 | 2.120 |
Why?
| | Patient Discharge | 11 | 2022 | 896 | 2.100 |
Why?
| | Middle Aged | 141 | 2025 | 33200 | 2.090 |
Why?
| | Laryngoscopy | 10 | 2025 | 109 | 2.070 |
Why?
| | Length of Stay | 21 | 2025 | 1208 | 2.050 |
Why?
| | Antibodies, Monoclonal | 11 | 2025 | 1428 | 2.050 |
Why?
| | Antibodies, Neutralizing | 9 | 2025 | 282 | 1.980 |
Why?
| | United States | 96 | 2025 | 14660 | 1.960 |
Why?
| | Oxygen | 12 | 2025 | 933 | 1.930 |
Why?
| | Influenza Vaccines | 14 | 2025 | 539 | 1.900 |
Why?
| | Laryngoscopes | 9 | 2025 | 38 | 1.870 |
Why?
| | Respiration, Artificial | 11 | 2024 | 642 | 1.840 |
Why?
| | Ritonavir | 3 | 2023 | 73 | 1.750 |
Why?
| | Male | 167 | 2025 | 67361 | 1.740 |
Why?
| | Respiratory Tract Infections | 8 | 2025 | 396 | 1.720 |
Why?
| | Hospitals | 9 | 2023 | 677 | 1.670 |
Why?
| | Antiviral Agents | 9 | 2025 | 736 | 1.630 |
Why?
| | Patient Transfer | 5 | 2015 | 165 | 1.620 |
Why?
| | Female | 164 | 2025 | 72840 | 1.580 |
Why?
| | Health Services Accessibility | 11 | 2019 | 976 | 1.430 |
Why?
| | Oxygen Inhalation Therapy | 5 | 2025 | 160 | 1.380 |
Why?
| | Patient Readmission | 5 | 2022 | 695 | 1.380 |
Why?
| | Antibodies, Viral | 8 | 2025 | 622 | 1.370 |
Why?
| | Vitamins | 8 | 2025 | 177 | 1.320 |
Why?
| | Cross-Sectional Studies | 35 | 2025 | 5417 | 1.310 |
Why?
| | Adenosine Monophosphate | 4 | 2024 | 66 | 1.270 |
Why?
| | Aged, 80 and over | 37 | 2025 | 7569 | 1.270 |
Why?
| | Retrospective Studies | 44 | 2024 | 15564 | 1.250 |
Why?
| | Alanine | 4 | 2024 | 151 | 1.240 |
Why?
| | Patient Admission | 7 | 2017 | 191 | 1.210 |
Why?
| | Health Care Rationing | 2 | 2024 | 59 | 1.210 |
Why?
| | Adolescent | 65 | 2025 | 21463 | 1.200 |
Why?
| | Nursing Homes | 3 | 2015 | 167 | 1.170 |
Why?
| | Intensive Care Units | 8 | 2025 | 802 | 1.150 |
Why?
| | Brain Injuries, Traumatic | 2 | 2023 | 358 | 1.140 |
Why?
| | Rural Health Services | 8 | 2020 | 127 | 1.080 |
Why?
| | Young Adult | 47 | 2025 | 13126 | 1.080 |
Why?
| | Physicians | 10 | 2023 | 897 | 1.050 |
Why?
| | Medicaid | 4 | 2015 | 433 | 1.050 |
Why?
| | Airway Management | 3 | 2024 | 52 | 1.040 |
Why?
| | Health Care Surveys | 17 | 2020 | 563 | 1.040 |
Why?
| | Pneumonia | 5 | 2021 | 638 | 1.010 |
Why?
| | Diabetes Mellitus | 7 | 2024 | 1033 | 0.980 |
Why?
| | Stroke | 6 | 2025 | 1129 | 0.970 |
Why?
| | Nurse Practitioners | 4 | 2012 | 135 | 0.960 |
Why?
| | Rehabilitation Centers | 2 | 2015 | 38 | 0.940 |
Why?
| | Treatment Outcome | 33 | 2025 | 10764 | 0.940 |
Why?
| | Mass Screening | 7 | 2012 | 1262 | 0.930 |
Why?
| | Vaccination | 19 | 2025 | 1378 | 0.910 |
Why?
| | Referral and Consultation | 6 | 2022 | 777 | 0.910 |
Why?
| | Insurance, Health | 5 | 2020 | 278 | 0.880 |
Why?
| | Shock, Traumatic | 1 | 2023 | 14 | 0.820 |
Why?
| | Medically Uninsured | 3 | 2014 | 129 | 0.820 |
Why?
| | Military Personnel | 4 | 2023 | 542 | 0.810 |
Why?
| | Respiratory Syncytial Virus Infections | 4 | 2025 | 128 | 0.810 |
Why?
| | Potentially Inappropriate Medication List | 1 | 2022 | 16 | 0.770 |
Why?
| | Health Services Needs and Demand | 3 | 2013 | 268 | 0.750 |
Why?
| | Minority Groups | 2 | 2023 | 267 | 0.750 |
Why?
| | Brain Ischemia | 4 | 2025 | 341 | 0.740 |
Why?
| | Inappropriate Prescribing | 1 | 2022 | 55 | 0.740 |
Why?
| | Internship and Residency | 8 | 2023 | 1131 | 0.720 |
Why?
| | Pneumonia, Viral | 6 | 2020 | 368 | 0.720 |
Why?
| | Coronavirus Infections | 6 | 2020 | 359 | 0.710 |
Why?
| | Surgical Procedures, Operative | 3 | 2025 | 257 | 0.710 |
Why?
| | Primary Health Care | 6 | 2019 | 1714 | 0.710 |
Why?
| | Asthma | 11 | 2012 | 2290 | 0.700 |
Why?
| | Prospective Studies | 24 | 2025 | 7583 | 0.690 |
Why?
| | Patient Outcome Assessment | 2 | 2021 | 130 | 0.690 |
Why?
| | Double-Blind Method | 18 | 2025 | 1981 | 0.680 |
Why?
| | Career Choice | 3 | 2010 | 215 | 0.660 |
Why?
| | Substance Abuse Detection | 1 | 2021 | 89 | 0.650 |
Why?
| | Resuscitation Orders | 2 | 2019 | 44 | 0.640 |
Why?
| | Pandemics | 11 | 2023 | 1619 | 0.640 |
Why?
| | Critical Care | 5 | 2022 | 583 | 0.640 |
Why?
| | Personnel Selection | 2 | 2010 | 78 | 0.640 |
Why?
| | Tracheostomy | 1 | 2021 | 132 | 0.630 |
Why?
| | Randomized Controlled Trials as Topic | 15 | 2025 | 1455 | 0.630 |
Why?
| | Warfare | 1 | 2019 | 68 | 0.630 |
Why?
| | Age Factors | 12 | 2019 | 3290 | 0.630 |
Why?
| | Machine Learning | 1 | 2024 | 487 | 0.620 |
Why?
| | Spine | 1 | 2021 | 173 | 0.620 |
Why?
| | Translating | 2 | 2010 | 43 | 0.610 |
Why?
| | Dietary Supplements | 8 | 2025 | 559 | 0.610 |
Why?
| | Hypoxia | 7 | 2025 | 1107 | 0.610 |
Why?
| | Resuscitation | 1 | 2021 | 250 | 0.610 |
Why?
| | Point-of-Care Systems | 4 | 2025 | 163 | 0.610 |
Why?
| | Triage | 3 | 2020 | 220 | 0.600 |
Why?
| | Cohort Studies | 17 | 2025 | 5718 | 0.600 |
Why?
| | Severity of Illness Index | 12 | 2024 | 2831 | 0.590 |
Why?
| | Conservative Treatment | 1 | 2018 | 32 | 0.580 |
Why?
| | Influenza A Virus, H1N1 Subtype | 3 | 2025 | 152 | 0.580 |
Why?
| | Acute Disease | 11 | 2025 | 1006 | 0.570 |
Why?
| | Communication Barriers | 2 | 2010 | 104 | 0.570 |
Why?
| | Anxiety | 1 | 2025 | 1032 | 0.560 |
Why?
| | Brain Injuries | 1 | 2023 | 490 | 0.550 |
Why?
| | Health Surveys | 4 | 2014 | 517 | 0.550 |
Why?
| | Influenza A Virus, H3N2 Subtype | 4 | 2025 | 46 | 0.540 |
Why?
| | Guideline Adherence | 6 | 2022 | 543 | 0.540 |
Why?
| | Interdisciplinary Studies | 1 | 2016 | 27 | 0.520 |
Why?
| | Financing, Organized | 1 | 2016 | 35 | 0.520 |
Why?
| | Hydroxychloroquine | 3 | 2022 | 58 | 0.520 |
Why?
| | Professional Autonomy | 2 | 2014 | 30 | 0.520 |
Why?
| | Sex Factors | 10 | 2019 | 2068 | 0.520 |
Why?
| | Acute Kidney Injury | 5 | 2025 | 811 | 0.520 |
Why?
| | Obesity | 4 | 2022 | 2975 | 0.510 |
Why?
| | Skilled Nursing Facilities | 2 | 2016 | 132 | 0.510 |
Why?
| | Language | 2 | 2010 | 296 | 0.500 |
Why?
| | Anti-Infective Agents | 2 | 2022 | 254 | 0.500 |
Why?
| | Surveys and Questionnaires | 11 | 2025 | 5749 | 0.500 |
Why?
| | Orthopedics | 1 | 2018 | 150 | 0.500 |
Why?
| | MicroRNAs | 3 | 2017 | 697 | 0.500 |
Why?
| | Databases, Factual | 10 | 2021 | 1347 | 0.500 |
Why?
| | Home Care Services | 2 | 2016 | 255 | 0.490 |
Why?
| | Communication | 2 | 2014 | 869 | 0.490 |
Why?
| | Colorado | 10 | 2025 | 4491 | 0.480 |
Why?
| | Boston | 8 | 2010 | 91 | 0.480 |
Why?
| | Multiple Trauma | 1 | 2016 | 101 | 0.480 |
Why?
| | Emergencies | 3 | 2015 | 164 | 0.470 |
Why?
| | Healthcare Disparities | 3 | 2012 | 649 | 0.470 |
Why?
| | Insurance Coverage | 3 | 2016 | 228 | 0.470 |
Why?
| | Respiratory Syncytial Virus Vaccines | 2 | 2025 | 36 | 0.460 |
Why?
| | Cross Infection | 2 | 2020 | 238 | 0.460 |
Why?
| | Pilot Projects | 7 | 2023 | 1697 | 0.460 |
Why?
| | Homes for the Aged | 1 | 2015 | 31 | 0.460 |
Why?
| | Hyperglycemia | 2 | 2009 | 346 | 0.460 |
Why?
| | Calcitriol | 3 | 2025 | 58 | 0.460 |
Why?
| | Catheterization, Central Venous | 1 | 2016 | 111 | 0.450 |
Why?
| | Halfway Houses | 1 | 2014 | 2 | 0.450 |
Why?
| | Acute Lung Injury | 3 | 2025 | 288 | 0.450 |
Why?
| | Electronic Health Records | 4 | 2024 | 1036 | 0.440 |
Why?
| | Shock, Septic | 4 | 2018 | 221 | 0.430 |
Why?
| | Organ Dysfunction Scores | 3 | 2024 | 47 | 0.430 |
Why?
| | Patient Compliance | 3 | 2008 | 576 | 0.420 |
Why?
| | Nutrition Surveys | 6 | 2011 | 267 | 0.420 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2014 | 95 | 0.420 |
Why?
| | Renin-Angiotensin System | 2 | 2025 | 84 | 0.420 |
Why?
| | Faculty, Medical | 1 | 2016 | 282 | 0.420 |
Why?
| | Betacoronavirus | 3 | 2020 | 267 | 0.420 |
Why?
| | Hospitals, Rural | 2 | 2010 | 39 | 0.410 |
Why?
| | Urban Health Services | 5 | 2020 | 63 | 0.410 |
Why?
| | Risk Factors | 14 | 2024 | 10331 | 0.410 |
Why?
| | Positive-Pressure Respiration | 3 | 2025 | 80 | 0.410 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 504 | 0.410 |
Why?
| | Time Factors | 16 | 2025 | 6792 | 0.410 |
Why?
| | Hypoglycemia | 2 | 2008 | 443 | 0.410 |
Why?
| | California | 5 | 2019 | 424 | 0.400 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2025 | 1323 | 0.400 |
Why?
| | Logistic Models | 8 | 2024 | 2060 | 0.400 |
Why?
| | International Educational Exchange | 1 | 2012 | 13 | 0.400 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 991 | 0.390 |
Why?
| | Medicare | 3 | 2015 | 747 | 0.390 |
Why?
| | International Classification of Diseases | 2 | 2014 | 131 | 0.390 |
Why?
| | Odds Ratio | 6 | 2018 | 1063 | 0.390 |
Why?
| | Renal Dialysis | 1 | 2016 | 434 | 0.380 |
Why?
| | Health Resources | 1 | 2013 | 122 | 0.380 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2017 | 351 | 0.380 |
Why?
| | Clinical Trials as Topic | 4 | 2024 | 1043 | 0.380 |
Why?
| | Treatment Failure | 6 | 2022 | 353 | 0.380 |
Why?
| | Oximetry | 2 | 2023 | 95 | 0.370 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2022 | 804 | 0.370 |
Why?
| | Multivariate Analysis | 6 | 2016 | 1513 | 0.370 |
Why?
| | Observation | 1 | 2011 | 50 | 0.370 |
Why?
| | Hospital Units | 1 | 2011 | 26 | 0.370 |
Why?
| | Patient Education as Topic | 4 | 2010 | 760 | 0.360 |
Why?
| | Military Medicine | 2 | 2022 | 63 | 0.360 |
Why?
| | Case-Control Studies | 13 | 2025 | 3537 | 0.360 |
Why?
| | Liability, Legal | 1 | 2011 | 43 | 0.360 |
Why?
| | Hyperparathyroidism, Secondary | 1 | 2011 | 12 | 0.360 |
Why?
| | Appointments and Schedules | 1 | 2011 | 89 | 0.360 |
Why?
| | Inflammation Mediators | 1 | 2014 | 514 | 0.360 |
Why?
| | Malpractice | 1 | 2011 | 42 | 0.360 |
Why?
| | Tomography, X-Ray Computed | 3 | 2017 | 2677 | 0.350 |
Why?
| | Patient Safety | 2 | 2016 | 304 | 0.350 |
Why?
| | Ambulatory Care | 5 | 2023 | 538 | 0.350 |
Why?
| | Biomarkers | 11 | 2025 | 4158 | 0.350 |
Why?
| | Influenza B virus | 3 | 2025 | 44 | 0.340 |
Why?
| | Training Support | 1 | 2010 | 31 | 0.340 |
Why?
| | Parathyroid Hormone | 1 | 2011 | 108 | 0.340 |
Why?
| | Personnel, Hospital | 2 | 2020 | 29 | 0.340 |
Why?
| | Inpatients | 2 | 2021 | 499 | 0.340 |
Why?
| | Interleukin-6 | 2 | 2025 | 778 | 0.340 |
Why?
| | Multicenter Studies as Topic | 5 | 2023 | 307 | 0.340 |
Why?
| | Digital Rectal Examination | 1 | 2010 | 10 | 0.330 |
Why?
| | Occult Blood | 1 | 2010 | 34 | 0.330 |
Why?
| | Blood Glucose | 3 | 2008 | 2180 | 0.330 |
Why?
| | Patient Care | 1 | 2010 | 110 | 0.320 |
Why?
| | Ambulances | 3 | 2023 | 51 | 0.320 |
Why?
| | Inflammation | 1 | 2021 | 2834 | 0.320 |
Why?
| | Risk Assessment | 8 | 2021 | 3429 | 0.320 |
Why?
| | Child | 22 | 2024 | 21968 | 0.310 |
Why?
| | Intrauterine Devices | 1 | 2009 | 30 | 0.310 |
Why?
| | Urban Population | 4 | 2025 | 472 | 0.310 |
Why?
| | Seasons | 7 | 2025 | 544 | 0.300 |
Why?
| | Cause of Death | 2 | 2017 | 429 | 0.290 |
Why?
| | Atracurium | 2 | 2019 | 14 | 0.290 |
Why?
| | Bias | 3 | 2024 | 218 | 0.290 |
Why?
| | Neuromuscular Blocking Agents | 2 | 2019 | 25 | 0.290 |
Why?
| | South Africa | 3 | 2023 | 219 | 0.290 |
Why?
| | Socioeconomic Factors | 5 | 2015 | 1281 | 0.280 |
Why?
| | Body Mass Index | 4 | 2019 | 2364 | 0.280 |
Why?
| | Mathematics | 1 | 2008 | 109 | 0.280 |
Why?
| | Registries | 4 | 2024 | 2015 | 0.280 |
Why?
| | Video Recording | 6 | 2025 | 181 | 0.270 |
Why?
| | Immunization, Passive | 2 | 2025 | 90 | 0.270 |
Why?
| | Medical Futility | 2 | 2024 | 23 | 0.270 |
Why?
| | Age Distribution | 4 | 2014 | 391 | 0.260 |
Why?
| | Noninvasive Ventilation | 2 | 2025 | 51 | 0.260 |
Why?
| | Influenza A virus | 2 | 2025 | 109 | 0.260 |
Why?
| | Disease Models, Animal | 1 | 2017 | 4279 | 0.260 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2009 | 1042 | 0.250 |
Why?
| | Magnetic Resonance Imaging | 2 | 2008 | 3566 | 0.250 |
Why?
| | Ivermectin | 2 | 2023 | 13 | 0.250 |
Why?
| | Decision Support Systems, Clinical | 2 | 2021 | 218 | 0.250 |
Why?
| | Data Collection | 4 | 2014 | 664 | 0.250 |
Why?
| | Emergency Treatment | 3 | 2019 | 117 | 0.240 |
Why?
| | Calcifediol | 1 | 2025 | 33 | 0.240 |
Why?
| | Oseltamivir | 1 | 2025 | 13 | 0.240 |
Why?
| | Prochlorperazine | 1 | 2025 | 7 | 0.240 |
Why?
| | Prevalence | 6 | 2014 | 2712 | 0.240 |
Why?
| | Community-Acquired Infections | 2 | 2020 | 171 | 0.240 |
Why?
| | Vasoconstrictor Agents | 3 | 2024 | 138 | 0.240 |
Why?
| | Wound Infection | 1 | 2025 | 32 | 0.240 |
Why?
| | Cognitive Dysfunction | 2 | 2021 | 385 | 0.230 |
Why?
| | Point-of-Care Testing | 1 | 2025 | 32 | 0.230 |
Why?
| | Renin | 1 | 2024 | 34 | 0.230 |
Why?
| | Oxazines | 1 | 2024 | 30 | 0.230 |
Why?
| | Pregnancy Complications | 1 | 2010 | 522 | 0.230 |
Why?
| | Hospitals, Urban | 3 | 2016 | 134 | 0.230 |
Why?
| | Vaccines, Synthetic | 5 | 2022 | 126 | 0.230 |
Why?
| | Cyclopropanes | 1 | 2024 | 90 | 0.230 |
Why?
| | Staphylococcal Infections | 1 | 2009 | 401 | 0.220 |
Why?
| | Glycocalyx | 1 | 2024 | 28 | 0.220 |
Why?
| | Antibiotic Prophylaxis | 1 | 2025 | 117 | 0.220 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2024 | 104 | 0.220 |
Why?
| | Glycine | 1 | 2025 | 175 | 0.220 |
Why?
| | Medical Audit | 2 | 2018 | 76 | 0.220 |
Why?
| | Choice Behavior | 2 | 2019 | 171 | 0.220 |
Why?
| | Acetates | 1 | 2024 | 99 | 0.220 |
Why?
| | Physician-Patient Relations | 1 | 2009 | 544 | 0.220 |
Why?
| | Morpholines | 1 | 2024 | 121 | 0.220 |
Why?
| | Ambulatory Care Facilities | 3 | 2020 | 230 | 0.220 |
Why?
| | Fluid Therapy | 2 | 2023 | 147 | 0.220 |
Why?
| | Heart Arrest | 2 | 2025 | 339 | 0.220 |
Why?
| | Incidence | 4 | 2025 | 2788 | 0.210 |
Why?
| | Sulfides | 1 | 2024 | 99 | 0.210 |
Why?
| | Chronic Disease | 3 | 2022 | 1784 | 0.210 |
Why?
| | Diabetic Ketoacidosis | 1 | 2006 | 202 | 0.210 |
Why?
| | Multiple Organ Failure | 1 | 2024 | 127 | 0.210 |
Why?
| | Hypotension | 2 | 2023 | 122 | 0.210 |
Why?
| | Altitude Sickness | 1 | 2025 | 152 | 0.210 |
Why?
| | Disease Progression | 5 | 2021 | 2750 | 0.210 |
Why?
| | Child, Preschool | 12 | 2019 | 11069 | 0.210 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 207 | 0.210 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2025 | 277 | 0.210 |
Why?
| | Anti-Bacterial Agents | 5 | 2025 | 1799 | 0.210 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2023 | 25 | 0.210 |
Why?
| | Quinolines | 1 | 2024 | 177 | 0.210 |
Why?
| | Androstadienes | 1 | 2023 | 107 | 0.210 |
Why?
| | Patient Acceptance of Health Care | 2 | 2020 | 806 | 0.200 |
Why?
| | Electronics | 1 | 2023 | 75 | 0.200 |
Why?
| | Immunocompromised Host | 2 | 2022 | 203 | 0.200 |
Why?
| | Comorbidity | 4 | 2021 | 1611 | 0.200 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2024 | 126 | 0.200 |
Why?
| | Lopinavir | 1 | 2022 | 30 | 0.200 |
Why?
| | Blood Transfusion | 1 | 2025 | 324 | 0.200 |
Why?
| | RNA, Messenger | 7 | 2023 | 2831 | 0.200 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2023 | 75 | 0.200 |
Why?
| | Plasma | 1 | 2024 | 213 | 0.200 |
Why?
| | Attitude of Health Personnel | 1 | 2010 | 1157 | 0.200 |
Why?
| | Urinary Tract Infections | 1 | 2004 | 168 | 0.190 |
Why?
| | Recovery of Function | 3 | 2022 | 655 | 0.190 |
Why?
| | Health Services Research | 2 | 2016 | 400 | 0.190 |
Why?
| | Delirium | 1 | 2023 | 86 | 0.190 |
Why?
| | Syncope | 1 | 2022 | 52 | 0.190 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2025 | 250 | 0.190 |
Why?
| | Cytokines | 2 | 2014 | 2088 | 0.190 |
Why?
| | Herpes Zoster Vaccine | 1 | 2024 | 159 | 0.180 |
Why?
| | Immunization, Secondary | 1 | 2022 | 89 | 0.180 |
Why?
| | Veterans Health | 1 | 2023 | 180 | 0.180 |
Why?
| | Metformin | 1 | 2025 | 329 | 0.180 |
Why?
| | Mountaineering | 2 | 2025 | 40 | 0.180 |
Why?
| | Acetaminophen | 1 | 2024 | 268 | 0.180 |
Why?
| | Long Term Adverse Effects | 1 | 2021 | 12 | 0.180 |
Why?
| | Polypharmacy | 1 | 2022 | 85 | 0.180 |
Why?
| | Malawi | 1 | 2021 | 53 | 0.180 |
Why?
| | Wounds, Penetrating | 1 | 2022 | 65 | 0.180 |
Why?
| | Immunization Programs | 1 | 2023 | 213 | 0.180 |
Why?
| | Drug Prescriptions | 1 | 2003 | 247 | 0.180 |
Why?
| | Academic Medical Centers | 4 | 2020 | 497 | 0.180 |
Why?
| | Health Policy | 1 | 2024 | 387 | 0.180 |
Why?
| | Vasodilator Agents | 1 | 2023 | 331 | 0.180 |
Why?
| | Sentinel Surveillance | 3 | 2025 | 47 | 0.180 |
Why?
| | Abdominal Pain | 1 | 2022 | 145 | 0.180 |
Why?
| | Work | 1 | 2020 | 18 | 0.180 |
Why?
| | Pyridines | 1 | 2024 | 505 | 0.170 |
Why?
| | Quality of Health Care | 3 | 2010 | 627 | 0.170 |
Why?
| | Rural Population | 3 | 2016 | 561 | 0.170 |
Why?
| | Bayes Theorem | 1 | 2022 | 400 | 0.170 |
Why?
| | Venous Thromboembolism | 1 | 2025 | 309 | 0.170 |
Why?
| | Burns | 1 | 2025 | 323 | 0.170 |
Why?
| | Telecommunications | 1 | 2020 | 21 | 0.170 |
Why?
| | Contact Tracing | 1 | 2020 | 24 | 0.170 |
Why?
| | Hemorrhage | 1 | 2025 | 723 | 0.170 |
Why?
| | Aftercare | 1 | 2022 | 209 | 0.170 |
Why?
| | Adrenergic beta-Agonists | 2 | 2012 | 133 | 0.170 |
Why?
| | Clinical Competence | 3 | 2025 | 1093 | 0.170 |
Why?
| | Neuromuscular Blockade | 2 | 2019 | 31 | 0.170 |
Why?
| | Personnel Turnover | 2 | 2010 | 41 | 0.170 |
Why?
| | Hypoglycemic Agents | 2 | 2025 | 1281 | 0.170 |
Why?
| | Abbreviated Injury Scale | 1 | 2019 | 22 | 0.160 |
Why?
| | Herpes Zoster | 1 | 2024 | 316 | 0.160 |
Why?
| | Chi-Square Distribution | 3 | 2012 | 532 | 0.160 |
Why?
| | Electrocardiography | 1 | 2003 | 628 | 0.160 |
Why?
| | Research Design | 2 | 2024 | 1107 | 0.160 |
Why?
| | Pulmonary Embolism | 2 | 2025 | 220 | 0.160 |
Why?
| | Iraq | 1 | 2019 | 53 | 0.160 |
Why?
| | Physical Therapy Modalities | 1 | 2023 | 308 | 0.160 |
Why?
| | Sensitivity and Specificity | 3 | 2025 | 1942 | 0.160 |
Why?
| | Agkistrodon | 1 | 2019 | 5 | 0.160 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2020 | 83 | 0.160 |
Why?
| | Infant | 7 | 2019 | 9442 | 0.160 |
Why?
| | Afghanistan | 1 | 2019 | 71 | 0.160 |
Why?
| | Respiratory Insufficiency | 1 | 2023 | 316 | 0.160 |
Why?
| | Computer Simulation | 1 | 2024 | 973 | 0.160 |
Why?
| | Symptom Assessment | 1 | 2020 | 125 | 0.160 |
Why?
| | Antivenins | 1 | 2019 | 36 | 0.160 |
Why?
| | Snake Bites | 1 | 2019 | 29 | 0.160 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2019 | 59 | 0.160 |
Why?
| | Continuity of Patient Care | 2 | 2012 | 278 | 0.160 |
Why?
| | Crotalid Venoms | 1 | 2019 | 31 | 0.160 |
Why?
| | Iraq War, 2003-2011 | 1 | 2019 | 127 | 0.160 |
Why?
| | Organ Transplantation | 1 | 2022 | 247 | 0.160 |
Why?
| | Dantrolene | 1 | 2019 | 6 | 0.150 |
Why?
| | Postoperative Complications | 2 | 2025 | 2624 | 0.150 |
Why?
| | Afghan Campaign 2001- | 1 | 2019 | 132 | 0.150 |
Why?
| | Adrenal Cortex Hormones | 5 | 2021 | 551 | 0.150 |
Why?
| | Neuromuscular Depolarizing Agents | 1 | 2019 | 4 | 0.150 |
Why?
| | Succinylcholine | 1 | 2019 | 4 | 0.150 |
Why?
| | Adaptive Clinical Trials as Topic | 3 | 2024 | 22 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2020 | 2045 | 0.150 |
Why?
| | Malignant Hyperthermia | 1 | 2019 | 10 | 0.150 |
Why?
| | Muscle Relaxants, Central | 1 | 2019 | 13 | 0.150 |
Why?
| | Lactic Acid | 1 | 2020 | 306 | 0.150 |
Why?
| | Quality Indicators, Health Care | 2 | 2012 | 308 | 0.150 |
Why?
| | Injury Severity Score | 2 | 2022 | 523 | 0.150 |
Why?
| | Needs Assessment | 3 | 2010 | 369 | 0.150 |
Why?
| | Platelet-Rich Plasma | 1 | 2018 | 32 | 0.150 |
Why?
| | Formative Feedback | 1 | 2018 | 28 | 0.150 |
Why?
| | Renal Replacement Therapy | 3 | 2025 | 92 | 0.150 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2019 | 72 | 0.150 |
Why?
| | Consensus | 1 | 2021 | 679 | 0.140 |
Why?
| | Biological Specimen Banks | 1 | 2018 | 102 | 0.140 |
Why?
| | Hospitals, Teaching | 2 | 2011 | 116 | 0.140 |
Why?
| | Vaccines | 1 | 2023 | 406 | 0.140 |
Why?
| | Time-to-Treatment | 4 | 2021 | 203 | 0.140 |
Why?
| | Survivors | 1 | 2021 | 487 | 0.140 |
Why?
| | Maryland | 1 | 2017 | 55 | 0.140 |
Why?
| | Certification | 3 | 2020 | 103 | 0.130 |
Why?
| | Specimen Handling | 1 | 2018 | 178 | 0.130 |
Why?
| | Civil Defense | 1 | 2017 | 19 | 0.130 |
Why?
| | Income | 2 | 2008 | 200 | 0.130 |
Why?
| | Infusions, Intravenous | 3 | 2024 | 408 | 0.130 |
Why?
| | Cognition | 2 | 2023 | 1166 | 0.130 |
Why?
| | Fibroblast Growth Factors | 1 | 2018 | 171 | 0.130 |
Why?
| | Cardiovascular Diseases | 1 | 2009 | 2108 | 0.130 |
Why?
| | Assisted Living Facilities | 1 | 2016 | 18 | 0.130 |
Why?
| | Trachea | 3 | 2023 | 235 | 0.130 |
Why?
| | Respiratory Syncytial Viruses | 2 | 2024 | 52 | 0.130 |
Why?
| | Oxygen Consumption | 1 | 2019 | 696 | 0.130 |
Why?
| | Avalanches | 1 | 2016 | 2 | 0.130 |
Why?
| | Accidental Falls | 2 | 2016 | 188 | 0.130 |
Why?
| | Executive Function | 1 | 2021 | 448 | 0.130 |
Why?
| | Orthopedic Procedures | 1 | 2018 | 218 | 0.120 |
Why?
| | Educational Status | 2 | 2008 | 482 | 0.120 |
Why?
| | Advance Directives | 1 | 2016 | 70 | 0.120 |
Why?
| | Environmental Exposure | 1 | 2020 | 576 | 0.120 |
Why?
| | AIDS Serodiagnosis | 2 | 2012 | 24 | 0.120 |
Why?
| | Colitis, Ulcerative | 1 | 2017 | 135 | 0.120 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 840 | 0.120 |
Why?
| | Efficiency, Organizational | 1 | 2016 | 138 | 0.120 |
Why?
| | RNA, Viral | 3 | 2024 | 651 | 0.120 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 2030 | 0.120 |
Why?
| | Data Interpretation, Statistical | 2 | 2024 | 349 | 0.120 |
Why?
| | Awareness | 1 | 2015 | 104 | 0.120 |
Why?
| | Evidence-Based Medicine | 2 | 2016 | 738 | 0.110 |
Why?
| | Anesthesiology | 1 | 2016 | 85 | 0.110 |
Why?
| | Precision Medicine | 1 | 2018 | 426 | 0.110 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 584 | 0.110 |
Why?
| | Infant, Newborn | 3 | 2014 | 6046 | 0.110 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 234 | 0.110 |
Why?
| | Perioperative Care | 1 | 2016 | 180 | 0.110 |
Why?
| | Frail Elderly | 1 | 2015 | 129 | 0.110 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2014 | 25 | 0.110 |
Why?
| | Health Care Costs | 1 | 2017 | 385 | 0.110 |
Why?
| | Feasibility Studies | 3 | 2025 | 947 | 0.110 |
Why?
| | Creatinine | 1 | 2015 | 498 | 0.110 |
Why?
| | Confidence Intervals | 3 | 2010 | 328 | 0.110 |
Why?
| | Fluvoxamine | 2 | 2023 | 17 | 0.100 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 885 | 0.100 |
Why?
| | Risk | 2 | 2017 | 904 | 0.100 |
Why?
| | Patient-Centered Care | 2 | 2016 | 520 | 0.100 |
Why?
| | Crohn Disease | 1 | 2017 | 242 | 0.100 |
Why?
| | Pneumonia, Bacterial | 1 | 2014 | 116 | 0.100 |
Why?
| | Neoplasms | 1 | 2008 | 2644 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2020 | 939 | 0.100 |
Why?
| | Vaccines, Combined | 2 | 2022 | 48 | 0.100 |
Why?
| | Physician's Role | 1 | 2014 | 206 | 0.100 |
Why?
| | Quality Improvement | 1 | 2021 | 1152 | 0.100 |
Why?
| | Headache | 1 | 2013 | 151 | 0.100 |
Why?
| | Preventive Health Services | 2 | 2012 | 148 | 0.100 |
Why?
| | Trauma Centers | 2 | 2025 | 422 | 0.100 |
Why?
| | Hospital Costs | 1 | 2013 | 119 | 0.100 |
Why?
| | Antigens, Viral | 2 | 2024 | 180 | 0.100 |
Why?
| | Sampling Studies | 1 | 2012 | 100 | 0.090 |
Why?
| | Immune System | 1 | 2013 | 177 | 0.090 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1235 | 0.090 |
Why?
| | Oregon | 1 | 2011 | 72 | 0.090 |
Why?
| | Georgia | 1 | 2011 | 84 | 0.090 |
Why?
| | Neutrophils | 1 | 2017 | 1234 | 0.090 |
Why?
| | Sex Distribution | 2 | 2013 | 376 | 0.090 |
Why?
| | Massachusetts | 1 | 2011 | 170 | 0.090 |
Why?
| | HIV | 1 | 2012 | 233 | 0.090 |
Why?
| | Epithelial Cells | 1 | 2017 | 1093 | 0.090 |
Why?
| | ROC Curve | 2 | 2024 | 545 | 0.090 |
Why?
| | Drug Administration Schedule | 3 | 2019 | 783 | 0.090 |
Why?
| | Fractures, Bone | 1 | 2016 | 420 | 0.090 |
Why?
| | Professional Practice Location | 1 | 2010 | 29 | 0.090 |
Why?
| | Specialization | 1 | 2011 | 143 | 0.090 |
Why?
| | Statistics, Nonparametric | 2 | 2009 | 430 | 0.090 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2011 | 103 | 0.090 |
Why?
| | Viral Load | 2 | 2023 | 460 | 0.090 |
Why?
| | Health Care Reform | 1 | 2011 | 102 | 0.080 |
Why?
| | Legislation as Topic | 1 | 2010 | 4 | 0.080 |
Why?
| | Delegation, Professional | 1 | 2010 | 1 | 0.080 |
Why?
| | Medical Staff, Hospital | 1 | 2010 | 84 | 0.080 |
Why?
| | Emergency Nursing | 1 | 2010 | 22 | 0.080 |
Why?
| | Occupations | 1 | 2010 | 48 | 0.080 |
Why?
| | Medically Underserved Area | 1 | 2010 | 86 | 0.080 |
Why?
| | Mice, Knockout | 1 | 2017 | 2999 | 0.080 |
Why?
| | Allied Health Personnel | 1 | 2010 | 45 | 0.080 |
Why?
| | Workload | 1 | 2011 | 161 | 0.080 |
Why?
| | Albuterol | 1 | 2010 | 110 | 0.080 |
Why?
| | Medical Order Entry Systems | 1 | 2010 | 43 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1294 | 0.080 |
Why?
| | Mice, Inbred C57BL | 2 | 2017 | 5744 | 0.080 |
Why?
| | Geriatric Assessment | 1 | 2011 | 218 | 0.080 |
Why?
| | Social Class | 2 | 2009 | 277 | 0.080 |
Why?
| | Altitude | 1 | 2014 | 482 | 0.080 |
Why?
| | Population | 1 | 2009 | 35 | 0.080 |
Why?
| | Motivation | 2 | 2012 | 563 | 0.080 |
Why?
| | Algorithms | 1 | 2017 | 1686 | 0.080 |
Why?
| | Specialty Boards | 1 | 2009 | 36 | 0.080 |
Why?
| | Interprofessional Relations | 1 | 2011 | 280 | 0.080 |
Why?
| | Mental Health Services | 1 | 2014 | 414 | 0.080 |
Why?
| | Schools, Veterinary | 1 | 2008 | 2 | 0.080 |
Why?
| | Quality of Life | 1 | 2021 | 2868 | 0.080 |
Why?
| | Forced Expiratory Volume | 1 | 2010 | 532 | 0.080 |
Why?
| | Nutritional Status | 1 | 2011 | 344 | 0.070 |
Why?
| | Fatal Outcome | 1 | 2009 | 304 | 0.070 |
Why?
| | Professional Role | 1 | 2010 | 165 | 0.070 |
Why?
| | Job Satisfaction | 1 | 2010 | 215 | 0.070 |
Why?
| | Disease Management | 2 | 2011 | 623 | 0.070 |
Why?
| | Interleukin-10 | 1 | 2010 | 302 | 0.070 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 1059 | 0.070 |
Why?
| | Self Report | 2 | 2023 | 825 | 0.070 |
Why?
| | Device Removal | 1 | 2009 | 138 | 0.070 |
Why?
| | Nurses | 1 | 2010 | 173 | 0.070 |
Why?
| | Smoking Cessation | 1 | 2012 | 446 | 0.070 |
Why?
| | Mexican Americans | 1 | 2009 | 117 | 0.070 |
Why?
| | Insulin | 2 | 2009 | 2399 | 0.070 |
Why?
| | Glucocorticoids | 2 | 2023 | 596 | 0.070 |
Why?
| | Statistics as Topic | 1 | 2008 | 311 | 0.070 |
Why?
| | Mental Recall | 2 | 2021 | 201 | 0.070 |
Why?
| | Health Status Indicators | 1 | 2008 | 171 | 0.070 |
Why?
| | Immunity, Innate | 2 | 2014 | 826 | 0.070 |
Why?
| | Morbidity | 1 | 2008 | 322 | 0.070 |
Why?
| | Glucose Tolerance Test | 1 | 2008 | 364 | 0.070 |
Why?
| | Animals | 4 | 2019 | 36768 | 0.070 |
Why?
| | Forecasting | 1 | 2008 | 384 | 0.070 |
Why?
| | Administration, Inhalation | 2 | 2023 | 683 | 0.060 |
Why?
| | Liver Transplantation | 1 | 2014 | 871 | 0.060 |
Why?
| | Virus Diseases | 1 | 2008 | 214 | 0.060 |
Why?
| | Papillomavirus Vaccines | 1 | 2009 | 237 | 0.060 |
Why?
| | RNA | 2 | 2023 | 924 | 0.060 |
Why?
| | Proportional Hazards Models | 1 | 2009 | 1260 | 0.060 |
Why?
| | Geography | 1 | 2006 | 197 | 0.060 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2009 | 387 | 0.060 |
Why?
| | Picolinic Acids | 1 | 2025 | 9 | 0.060 |
Why?
| | History, 21st Century | 1 | 2006 | 211 | 0.060 |
Why?
| | Self Care | 1 | 2008 | 375 | 0.060 |
Why?
| | Angiotensin I | 1 | 2025 | 7 | 0.060 |
Why?
| | Papillomavirus Infections | 1 | 2009 | 324 | 0.060 |
Why?
| | Burn Units | 1 | 2025 | 48 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2008 | 1318 | 0.060 |
Why?
| | History, 20th Century | 1 | 2006 | 323 | 0.060 |
Why?
| | Perioperative Period | 1 | 2025 | 56 | 0.060 |
Why?
| | Cannula | 1 | 2025 | 22 | 0.060 |
Why?
| | Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2024 | 6 | 0.060 |
Why?
| | Staphylococcus aureus | 1 | 2009 | 452 | 0.060 |
Why?
| | Calcium | 1 | 2011 | 1197 | 0.060 |
Why?
| | Germany | 1 | 2025 | 121 | 0.060 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 2024 | 17 | 0.060 |
Why?
| | Androstanols | 1 | 2024 | 18 | 0.060 |
Why?
| | Leukotriene Antagonists | 1 | 2024 | 43 | 0.060 |
Why?
| | Feedback | 1 | 2025 | 173 | 0.060 |
Why?
| | Missouri | 1 | 2004 | 61 | 0.060 |
Why?
| | Pyridazines | 1 | 2024 | 56 | 0.060 |
Why?
| | Lung | 1 | 2017 | 4065 | 0.060 |
Why?
| | Equipment Reuse | 1 | 2024 | 16 | 0.050 |
Why?
| | Prognosis | 2 | 2020 | 4018 | 0.050 |
Why?
| | Sample Size | 1 | 2024 | 117 | 0.050 |
Why?
| | Qualitative Research | 2 | 2022 | 1359 | 0.050 |
Why?
| | Masks | 1 | 2024 | 62 | 0.050 |
Why?
| | Shock | 1 | 2024 | 95 | 0.050 |
Why?
| | Angiotensins | 1 | 2023 | 9 | 0.050 |
Why?
| | Early Diagnosis | 1 | 2024 | 243 | 0.050 |
Why?
| | Patient Acuity | 1 | 2023 | 47 | 0.050 |
Why?
| | Vaccines, Attenuated | 1 | 2024 | 131 | 0.050 |
Why?
| | Long-Term Care | 1 | 2024 | 100 | 0.050 |
Why?
| | Macrolides | 1 | 2003 | 63 | 0.050 |
Why?
| | Calibration | 1 | 2023 | 145 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2008 | 763 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2025 | 560 | 0.050 |
Why?
| | Nucleocapsid | 1 | 2022 | 17 | 0.050 |
Why?
| | Remission Induction | 1 | 2023 | 287 | 0.050 |
Why?
| | Angiotensin II | 1 | 2023 | 99 | 0.050 |
Why?
| | Drug Repositioning | 1 | 2022 | 35 | 0.050 |
Why?
| | Information Dissemination | 1 | 2024 | 217 | 0.050 |
Why?
| | Advisory Committees | 1 | 2024 | 219 | 0.050 |
Why?
| | Emergency Medical Dispatch | 1 | 2022 | 6 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 2024 | 268 | 0.050 |
Why?
| | Hemoglobins | 1 | 2024 | 353 | 0.050 |
Why?
| | Immunocompetence | 1 | 2022 | 42 | 0.050 |
Why?
| | Information Systems | 1 | 2022 | 60 | 0.050 |
Why?
| | Syndrome | 1 | 2022 | 357 | 0.050 |
Why?
| | Pulse Therapy, Drug | 1 | 2021 | 7 | 0.050 |
Why?
| | Health Promotion | 2 | 2022 | 736 | 0.050 |
Why?
| | Oligopeptides | 1 | 2023 | 272 | 0.040 |
Why?
| | Pyrimidines | 1 | 2024 | 470 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 664 | 0.040 |
Why?
| | Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 5 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2020 | 73 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2025 | 707 | 0.040 |
Why?
| | Immunization | 1 | 2023 | 410 | 0.040 |
Why?
| | Transplant Recipients | 1 | 2022 | 178 | 0.040 |
Why?
| | Antimalarials | 1 | 2020 | 31 | 0.040 |
Why?
| | Personnel Staffing and Scheduling | 2 | 2011 | 94 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2022 | 197 | 0.040 |
Why?
| | HIV Infections | 2 | 2012 | 2812 | 0.040 |
Why?
| | Documentation | 1 | 2022 | 189 | 0.040 |
Why?
| | Herpesvirus 3, Human | 1 | 2024 | 332 | 0.040 |
Why?
| | Personal Protective Equipment | 1 | 2020 | 52 | 0.040 |
Why?
| | Health Facilities | 1 | 2021 | 83 | 0.040 |
Why?
| | Seroepidemiologic Studies | 1 | 2020 | 163 | 0.040 |
Why?
| | Vaccination Coverage | 1 | 2021 | 81 | 0.040 |
Why?
| | Models, Statistical | 1 | 2024 | 658 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2020 | 87 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2009 | 5115 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2020 | 286 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2022 | 663 | 0.040 |
Why?
| | Ergocalciferols | 1 | 2019 | 13 | 0.040 |
Why?
| | Practice Guidelines as Topic | 2 | 2022 | 1568 | 0.040 |
Why?
| | Program Evaluation | 1 | 2003 | 886 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2003 | 481 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2024 | 916 | 0.040 |
Why?
| | Conscious Sedation | 1 | 2019 | 91 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2024 | 925 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 364 | 0.040 |
Why?
| | RNA Transport | 1 | 2017 | 23 | 0.030 |
Why?
| | Myocardial Infarction | 1 | 2025 | 1045 | 0.030 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 14 | 0.030 |
Why?
| | Informed Consent | 1 | 2018 | 169 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 891 | 0.030 |
Why?
| | Workflow | 1 | 2018 | 165 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 99 | 0.030 |
Why?
| | Pregnancy | 1 | 2010 | 6731 | 0.030 |
Why?
| | Africa | 1 | 2017 | 108 | 0.030 |
Why?
| | Historically Controlled Study | 1 | 2016 | 5 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 326 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2021 | 1054 | 0.030 |
Why?
| | Ghana | 1 | 2015 | 38 | 0.030 |
Why?
| | Cell Communication | 1 | 2017 | 314 | 0.030 |
Why?
| | Reimbursement, Incentive | 1 | 2015 | 37 | 0.030 |
Why?
| | Cathelicidins | 1 | 2014 | 41 | 0.030 |
Why?
| | Mortality | 1 | 2017 | 357 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 2014 | 205 | 0.030 |
Why?
| | Depression | 1 | 2023 | 1402 | 0.030 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2014 | 81 | 0.030 |
Why?
| | Muscle Strength | 1 | 2017 | 317 | 0.030 |
Why?
| | Clinical Coding | 1 | 2013 | 22 | 0.030 |
Why?
| | Internet | 1 | 2017 | 648 | 0.020 |
Why?
| | Bed Occupancy | 1 | 2011 | 16 | 0.020 |
Why?
| | Nanoparticles | 1 | 2017 | 484 | 0.020 |
Why?
| | Domestic Violence | 1 | 2011 | 53 | 0.020 |
Why?
| | Salmeterol Xinafoate | 1 | 2010 | 41 | 0.020 |
Why?
| | Pamphlets | 1 | 2010 | 23 | 0.020 |
Why?
| | Resource Allocation | 1 | 2010 | 51 | 0.020 |
Why?
| | Demography | 1 | 2010 | 291 | 0.020 |
Why?
| | Tobacco Use Disorder | 1 | 2012 | 252 | 0.020 |
Why?
| | Consumer Health Information | 1 | 2010 | 46 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2847 | 0.020 |
Why?
| | Self Efficacy | 1 | 2012 | 394 | 0.020 |
Why?
| | Psychometrics | 1 | 2012 | 721 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2012 | 650 | 0.020 |
Why?
| | Research | 1 | 2011 | 445 | 0.020 |
Why?
| | Teaching | 1 | 2010 | 226 | 0.020 |
Why?
| | Linear Models | 1 | 2009 | 845 | 0.020 |
Why?
| | Anti-Asthmatic Agents | 1 | 2010 | 393 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2012 | 3272 | 0.010 |
Why?
|
|
Ginde's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|